StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
ILMN's strong Q3 results and raised guidance indicate robust financial health. Historically, similar beats have led to sustained price increases.
What happened, with direct paths to the underlying reporting
ILMN reports Q3 earnings of $1.34, exceeding consensus expectations of $1.17. Revenue of $1.084 billion beats forecasts, showing strong clinical market performance. Fiscal 2025 earnings guidance raised to $4.65-$4.75 per share, above consensus. New operating margin estimates increased to between 22.75% and 23% for 2025. Evercore ISI raises ILMN price target from $132 to $142, maintaining Outperform rating.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.